Kappa Free Light Chain Index Distinguishes MS From Clinical Mimics

Establishing an accurate diagnosis in patients presenting with inflammatory demyelinating syndromes remains a significant clinical challenge, as multiple sclerosis often mimics other neuroinflammatory conditions [1]. While the detection of cerebrospinal fluid restricted oligoclonal bands has long served as the gold standard for identifying intrathecal immunoglobulin synthesis, the test is qualitative and subject to rater interpretation [2]. Recent updates to diagnostic criteria have emphasized the need for more objective biomarkers to confirm central nervous system inflammation and predict disease progression [3]. The kappa free light chain index, a quantitative measure of immunoglobulin subunits produced during the immune response, has emerged as a potential alternative with diagnostic sensitivity and specificity comparable to traditional methods [4, 5]. A new multicenter study now provides evidence on how this biomarker performs when specifically tasked with distinguishing multiple sclerosis from its most common clinical mimics, offering clinicians a more standardized tool to guide early treatment decisions.